Discover the DAXXIFY® Difference

Experience the first and only peptide-formulated neuromodulator[1-6]

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Please see additional Important Safety Information throughout.

The difference is in the formulation

Not all neuromodulators are the same.[1-6]

2002

For two decades, traditional neuromodulators were formulated with human serum albumin (HSA)[2-5,7,8*]

2009

2011

2019

DAXXIFY® is the first neuromodulator innovation in over 20 years with a peptide formulation[1-5,7,8*]

2022

The results speak for themselves

DAXXIFY® delivers clinically proven outcomes that are:

Fast acting[10†]
Long lasting[11‡]
Radiant looking[12§]



Actual patient. Results may vary.

TODAY, DAXXIFY® IS THE FASTEST GROWING NEUROMODULATOR IN THE USA.[9]

Over **1 MILLION** vials sold.[¶]

TALK TO YOUR PATIENTS ABOUT DAXXIFY® RESULTS THAT ACHIEVED 96% SATISFACTION.[11#]

*All neuromodulators are formulated with a core active neurotoxin and other excipients.

†Onset as early as day 1 and typically within 2 days. Based on pooled patient diary data from SAKURA 1 and SAKURA 2.[1,10,11]

‡More than 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator's and patient's assessments.[13] 74% achieved a ≥2-grade improvement at week 4 per both investigator's and patient's assessments.[1,11]

§In an open-label study (N=27), 89% of patients agreed their skin looked radiant/bright (exploratory endpoint).[12]

¶September 2022 through September 2025.

#Per pooled data from SAKURA 1 and SAKURA 2, 96% of patients were satisfied with their treatment at week 4.[1,11]

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please see additional Important Safety Information throughout.

DAXXIFY® is the only peptide-formulated neuromodulator[1-6]

DAXXIFY® is a purified 150-kDa BoNT/A formulated with a proprietary, custom-engineered, 35-amino-acid stabilizing excipient peptide that has a highly positive charge.[1,14,15]

Enhances attachment

Our positively charged peptide forms a powerful bond with the neuron.[16]

Sustains delivery

This bond helps keep more of the active ingredient available over time.[16]

Stabilizes the active ingredient

The peptide helps stabilize the core neuromodulator—eliminating the need for human blood components.[1,17]

For illustrative purposes only

DAXXIFY®
daxibotulinumtoxinA-lanm injection

*Aesthetics consumers asked in a survey if they are interested in having peptides in a neurotoxin treatment. N=1000.

IMPORTANT SAFETY INFORMATION (cont)

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Please see additional Important Safety Information throughout.

DID YOU KNOW?

73% of aesthetics patients say they are interested in a peptide-formulated neuromodulator.[18*]

Peptide formulation boosts uptake of BoNT/A[19]

DAXXIFY® uses a novel peptide that helps the BoNT/A form a magnet-like bond with the neuron to help efficiently deliver the active ingredient.[16]

The peptide helps the BoNT/A create a strong attachment to the neuron, allowing for more BoNT/A to be absorbed. Over time, less active ingredient will be washed out by the body's natural process, with more active ingredient available to be effective.[19]

A MAGNET-LIKE BOND FORMS WITH THE NEURON[16,20,21]



The BoNT/A surface is positively and negatively charged.

The peptide is positively charged.

The peptide binds electrostatically to BoNT/A to create a new net-positively charged complex.

The positively charged peptide-toxin complex attaches to negatively charged neuronal receptors.



SEE THE SCIENCE IN ACTION

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Binds efficiently to the neuron[16,19]

DAXXIFY® was studied in an in vitro human neuronal experiment where increasing the peptide concentration enhanced BoNT/A binding to the neurons, while increasing HSA did not.[19*]



Our unique peptide formulation strengthens the binding to the neuron—allowing for more BoNT/A to enter the neuron over time.[16]

DID YOU KNOW?

~2/3 of aesthetics patients say they would switch to a different neuromodulator based on its ingredients/formulation.[22†]

*Based on pre-clinical data, the clinical relevance of this mechanism has not been confirmed in comparative studies. This comparison evaluates daxibotulinumtoxinA formulated with the peptide (RTP004) vs the same core 150-kDa botulinum toxin formulated with HSA.[19]

†Aesthetics consumers asked in a survey if they would switch to another neurotoxin brand based on its ingredients/formulation. N=2000.[22]

IMPORTANT SAFETY INFORMATION (cont)

Adverse Reactions

The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Please see additional Important Safety Information throughout.

Ready to deliver the DAXXIFY® Difference to your patients?

Fast-acting, long-lasting, radiant-looking results they'll love.[10-12]*

94%

of patients prefer DAXXIFY® over their previous neuromodulator.[23]†

90%

of patients are interested in learning about DAXXIFY® from their provider.[24]‡

DAXXIFY®
daxibotulinumtoxinA-lanm injection

*Onset as early as day 1 and typically within 2 days. Based on pooled patient diary data from SAKURA 1 and SAKURA 2.[1,10,11] More than 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator's and patient's assessments.[13] 74% achieved a ≥2-grade improvement at week 4 per both investigator's and patient's assessments.[1,11] In an open-label study (N=27), 89% of patients agreed their skin looked radiant/bright (exploratory endpoint).[12]

†Based on a survey of 149 patients at week 2.

‡Aesthetics consumers asked in a survey after they read about DAXXIFY®, which of the following describes them best: I would like to find a provider that offers DAXXIFY®, I want to talk to my provider about DAXXIFY®, I am hesitant to try DAXXIFY®. N=728.[24]

IMPORTANT SAFETY INFORMATION (cont)

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Please see additional Important Safety Information throughout.

Fast acting[10*]

DAXXIFY® onset is as early as

DAY 1

Typically within

2 DAYS[10*]

Actual patient.

BEFORE

2 DAYS AFTER

Results may vary.

"I loved how DAXXIFY® took effect quickly. It's awesome!"

– Michelle (38)

*Based on pooled patient diary data from SAKURA 1 and SAKURA 2.[1,11]

†More than 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator's and patient's assessments.[13] 74% achieved a ≥2-grade improvement at week 4 per both investigator's and patient's assessments.[1,11]

Long lasting[11†]

DAXXIFY®
daxibotulinumtoxinA-lanm injection

BEFORE

2 WEEKS AFTER

4 MONTHS AFTER

6 MONTHS AFTER

Results may vary.

"After six months, I see fewer [frown] lines. It's incredible."

– Mariana (40s)

IMPORTANT SAFETY INFORMATION (cont)

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see additional Important Safety Information throughout.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

Natural looking with gradual softening[11,12*†]

IN A CLINICAL STUDY,

96% of patients agreed that DAXXIFY® results looked natural.[12*]

WHEN ASKED ABOUT DESIRED OUTCOMES,

88% of patients said they don't want to look frozen to prevent wrinkles.[24‡]

In Phase 3 studies, DAXXIFY® exhibits fast onset, peak efficacy at 4 weeks, and then a **gradual softening over a prolonged period**.[11†]

GLABELLAR LINES NONE OR MILD RESPONDER RATES PER INVESTIGATOR'S ASSESSMENT



*In an open-label study (N=27), 96% of patients agreed their skin looked natural (exploratory endpoint).[12]
†Median time to return to baseline wrinkle severity was 27.7 weeks in SAKURA 1 and 26 weeks in SAKURA 2.[13]
‡Aesthetics consumers asked in a survey what are their treatment goals when getting aesthetic injectable treatments. N=720.[24]

DAXXIFY®
daxibotulinumtoxinA-lanm injection

SEE THE SLOW RETURN TO MOVEMENT

Over time, patients experience a gradual wear-off with DAXXIFY®.[11†]

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

IMPORTANT SAFETY INFORMATION (cont)

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Please see additional Important Safety Information throughout.

Radiant looking[12*]

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Revance conducted the only study of its kind to evaluate the appearance of skin quality and texture with DAXXIFY®.[12*]

DAXXIFY® IMPROVES THE APPEARANCE OF SKIN RADIANCE AND BRIGHTNESS[12*]

The qualitative survey assessment resulted in:

~90% of DAXXIFY® patients reported their skin looked radiant and bright in the glabella.[12*]

DAXXIFY® SMOOTHS THE DEEPEST OF LINES[11,25,26]

96% of DAXXIFY® patients agreed their skin looked smooth in the glabella.[12*]

*In an open-label study (N=27), 89% of patients agreed their skin looked radiant/bright, and 96% of patients agreed their skin looked smooth in the glabella (exploratory endpoints).[12]

IMPORTANT SAFETY INFORMATION (cont)

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please see additional Important Safety Information throughout.

IMAGING RESULTS



Results may vary.

Proven efficacy and consistency[11]

Backed by the largest Phase 3 clinical trial program in glabellar lines, DAXXIFY® achieved optimal outcomes with 40 Units on-label dosing for all Fitzpatrick Skin Types (I-VI).[15,27]

- Consistent results were seen across all SAKURA trials

65
TRIAL SITES[15,27]

2,823
PATIENTS[27]

4,444
TREATMENTS[27]

21
MONTHS[15]

98%

achieved wrinkle severity of none or mild at week 4 per investigator's assessment.[11]*

88%

achieved ≥2-grade improvement at week 4 per investigator's assessment. 74% achieved ≥2-grade improvement at week 4 per both investigator's and patient's assessments.[1,11]

*Per pooled data from SAKURA 1 and SAKURA 2.[1,11]

No serious treatment-related adverse events[1,11]

Across clinical trials, DAXXIFY® was generally safe and well tolerated.[1,11]

ADVERSE REACTIONS ≥1% AND MORE FREQUENT THAN PLACEBO IN SAKURA 1 AND SAKURA 2 (POOLED)[1]	DAXXIFY® N=406 n (%)	PLACEBO N=203 n (%)
HEADACHE	26 (6%)	4 (2%)
EYELID PTOSIS	9 (2%)	0 (0%)
FACIAL PARESIS†	5 (1%)	0 (0%)

- In the repeat-dose, open-label SAKURA 3 safety study, 2,691 patients were treated with 40U of DAXXIFY®. The adverse reaction profile was similar to that reported in single-dose trials[1,27]
- Injection site reactions were the most common adverse reactions, reported in 9% of patients [including injection site pain (4%), injection site erythema (3%), injection site edema (3%), injection site bruising (1%), injection site papule (<1%), and injection site pruritus (<1%)], followed by headache (5%), edema (2%), erythema (2%), and eyelid ptosis in 1% of patients[1]
- The incidence of these adverse reactions did not increase with multiple retreatments[1]

†Facial paresis, including facial asymmetry, is a broad term in the adverse event coding system, and in SAKURA 1 and SAKURA 2 this included 1 patient with unilateral over-arched brow and 4 patients with frontalis muscle weakness.[1,28]

Comprehensive practice support

At Revance, partnering with providers is of the utmost importance to help support your success with DAXXIFY®.

EDUCATION

Get comprehensive clinical training for DAXXIFY®.

- Online Modules
- Virtual Workshops
- Educational Events

INTEGRATION

Choose from a range of marketing tools to easily integrate DAXXIFY® into your practice.

- Business Building
- Social Posts
- Swag

OPTIMIZATION

Learn how to get optimal DAXXIFY® results.

SCAN TO WATCH DOSING AND RECONSTITUTION.

ACQUISITION

Increase your practice visibility and search discoverability online—driving new DAXXIFY® patients directly to your practice.

BOOST PATIENT INTEREST WITH THOUSANDS OF POTENTIAL VIEWS.



Become a DAXXIFY® provider today!

DAXXIFY®
daxibotulinumtoxinA-lanm injection

IMPORTANT SAFETY INFORMATION (cont)

Warnings and Precautions
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Please see additional Important Safety Information throughout.

DAXXIFY®
daxibotulinumtoxinA-lanm injection

Discover the DAXXIFY® Difference

Fastest growing neuromodulator in the USA.[9]

Over 1 MILLION vials sold since 2022 launch.

The only neuromodulator manufactured in the USA.[1-6]

REFERENCES

1. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023.
2. BOTOX® Cosmetic. Prescribing Information. Allergan, Inc; 2023.
3. DYSPORT®. Prescribing Information. Ipsen Biopharm Ltd; 2023.
4. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
5. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2024.
6. Letybo®. Prescribing Information. Hugel America, Inc; 2024.
7. FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity in Adults. PR Newswire website. Published October 3, 2017. Accessed October 10, 2025.
8. Merz Aesthetics Announces FDA Approval of XEOMIN® (incobotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Glabellar Lines in Adult Patients. PR Newswire. Published July 21, 2011. Accessed October 10, 2025.
9. Data on File. US Facial Injectables Market Tracker Cosmetic Neurotoxins and Dermal Fillers Q2-2021 through Q1-2025. Newark, CA: Revance Therapeutics, Inc, 2025.
10. Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2021.
11. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). *J Am Acad Dermatol*. 2020;82(4):838-845.
12. Biesman B, Curcio N, Stephenson J, et al. RADIANCE: Clinically meaningful improvements in skin quality after treatment with daxibotulinumtoxinA-lanm. Poster presented at: American Society for Dermatologic Surgery Annual Meeting; November 13-16, 2025; Chicago, IL.
13. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). *Plast Reconstr Surg*. 2020;145(1):45-58.
14. Waugh JM, Lee J, Dake MD, Browne D. Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development. *Methods Mol Biol*. 2011;683:553-572.
15. Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. *Dermatol Surg*. 2020;47(1):48-54.
16. Pulkoski-Gross MJ, Fang C, Shai R, Too P. A cell-penetrating peptide binds directly to and enhances membrane binding of the core toxin of botulinum toxin type A (BoNTA). Poster presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA.
17. Solish N, Carruthers J, Kaufman J, Rubio R, Gross TM, Gallagher CJ. Overview of DaxibotulinumtoxinA for Injection: a novel formulation of botulinum toxin type A. *Drugs*. 2021;81(18):2091-2101.
18. Data on File. Insights First Strategic Marketing. DAXXIFY® Awareness Tracker. Newark, CA: Revance Therapeutics, Inc, 2025.
19. Batista AF, Pulkoski-Gross MJ, Singh R, et al. A cell-penetrating peptide enhances membrane binding of botulinum neurotoxin type A and increases SNAP-25 cleavage. *Toxicon*. 2024; 237(S1):107364.
20. Mariwalla K, Shamban A, Green J, et al. Clinical benefits of DaxibotulinumtoxinA for Injection: beyond glabellar line effacement. *Dermatol Surg*. 2024;50(9S):S18-S23.
21. Carruthers J, Solish N, Humphrey S, et al. Injectable DaxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. *Dermatol Surg*. 2017;40(11):1321-1331.
22. Data on File. Talker Research Ingredients Fanatics. Newark, CA: Revance Therapeutics, Inc; 2025.
23. Data on File. DAXXIFY® Patient Survey. Newark, CA: Revance Therapeutics, Inc; 2022.
24. Data on File. Insights First Strategic Marketing. Skin Rejuvenation Patient Segmentation BOTULINUM TOXIN & HA DERMAL FILLER. Final Report. Newark, CA: Revance Therapeutics, Inc; 2025.
25. Data on File. Gross. American Academy of Dermatology. Newark, CA: Revance Therapeutics, Inc, 2021.
26. Brown J, Stephenson J, Kooken K, Sparrow J. Impact of DaxibotulinumtoxinA for Injection on skin smoothness following treatment of glabellar lines. Poster presented at: Derm2023 NP/PA CME Conference; August 3-6, 2023; Las Vegas, NV.
27. Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. *Dermatol Surg*. 2021;47(1):42-46.
28. Data on File. Sak_1_and_Sak_2_facial paresis-asymmetry. Newark, CA: Revance Therapeutics, Inc, 2018.

REVANCE AESTHETICS.